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Prognostic Impact of Fibroblast Growth Factor 2 in
Non-small Cell Lung Cancer
Coexpression with VEGFR-3 and PDGF-B Predicts Poor Survival
Tom Donnem, MD,*† Khalid Al-Shibli, MD,‡§ Samer Al-Saad, MD,‡ Lill-Tove Busund, MD, PhD,‡
and Roy M. Bremnes, MD, PhD*†
Purpose: Fibroblast growth factor 2 (FGF2; basic fibroblast growth
factor, b-FGF) and its main receptor FGFR-1 are important in both
hemangiogenesis and lymphangiogenesis. Murine studies have in-
dicated a close interplay between both FGF2 and platelet-derived
growth factor–B (PDGF-B) as well as FGF2 and vascular endothe-
lial growth factor-3 (VEGFR-3). This study investigates the prog-
nostic impact of FGF2 and FGFR-1 in tumor cells and tumor stroma
of resected non-small cell lung carcinomas (NSCLC) and explores
the importance of their coexpression with VEGFR-3 or PDGF-B.
Methods: Tumor tissue samples from 335 resected patients with
stage I to IIIA NSCLC were obtained and tissue microarrays were
constructed from duplicate cores of tumor cells and tumor-related
stroma from each specimen. Immunohistochemistry was used to
evaluate the expression of the molecular markers FGF2, FGFR-1,
VEGFR-3, and PDGF-B.
Results: In univariate analyses, high tumor cell FGF2 expression
(p  0.015) was a negative prognostic indicator for disease-specific
survival. In tumor stroma, high FGF2 (p  0.024) expression
correlated with good prognosis. In multivariate analyses, high ex-
pression of FGF2 in tumor cells (p  0.038) was an independent
negative prognostic factor whereas increased FGF2 in stroma (p 
0.015) was a positive prognosticator. Tumor cell coexpressions of
FGF2/VEGFR-3 (p  0.001) and FGFR-1/PDGF-B (p  0.002)
were significant indicators of poor prognosis.
Conclusions: Expression of FGF2 in tumor cells is an independent
negative prognostic factor, and the coexpressions of FGF2/VEGFR-3
and FGFR-1/PDGF-B are strongly associated with poor survival in
NSCLC patients.
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(J Thorac Oncol. 2009;4: 578–585)
Lung cancer is the leading cause of cancer-related mortalityin both men and women.1 The most important prognostic
variable for survival in non-small cell lung cancer (NSCLC)
has been tumor stage, primarily because early stage disease is
amenable to complete surgical resection and hitherto only
patients who undergo curative surgery have a significant
potential for cure.2,3 Several biochemical and clinical char-
acteristics have been investigated to assess their prognostic
and/or predictive relevance. In the era of new targeted ther-
apies, identifying the patients most likely to benefit from such
treatment is becoming increasingly important.
Angiogenesis, the process of new blood vessel forma-
tion from preexisting ones, plays a key role in tumor growth.4
The fibroblast growth factor (FGF) family represents a group
of heparin-binding, multifunctional polypeptides with mito-
gen activity which also is involved in angiogenesis.5 Fibroblast
growth factor 2 (FGF2; basic fibroblast growth factor, b-FGF) is
considered a potent stimulator of angiogenesis and binds with
high affinity mainly to fibroblast growth factor receptor-1
(FGFR-1), a tyrosine kinase receptor.4 FGF2 may exert its effect
on endothelial cells via a paracrine mode as a consequence to its
release by tumor and stromal cells. It is also suggested that FGF2
plays an autocrine role in endothelial cells.4,6
Previous data on FGF2’s prognostic impact in NSCLC
has been conflicting.7–12 Some studies report tumor cell FGF2
expression to correlate with poor survival8,10,11 although other
studies find no such association.9,12 In one study, however, an
inverse correlation between stromal FGF2 expression and
lymph node metastasis was observed.13 Several NSCLC stud-
ies have explored the prognostic role of elevated serum-
FGF2, but no consensus has been reached.7,14–18
Although the activity of individual angiogenic factors is
relatively well studied, less is known about the interplay
between various tumor-produced angiogenic factors and their
cooperative efforts in promoting tumor neovascularization.
Interestingly, a recent study using murine fibrosarcomas re-
ports a reciprocal interaction between FGF2 and platelet-
derived growth factor-B (PDGF-B) through their tyrosine
kinase receptors, FGFR-1 and PDGFR-.19,20
An intimate cross-talk between FGF2 and different
members of the VEGFs during hemangiogenesis and lym-
phangiogenesis has been proposed. Kubo et al.21 reported that
blockade of vascular endothelial growth factor-3 (VEGFR-3)
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signaling inhibits FGF2-induced lymphangiogenesis in mouse
cornea. We have previously reported on the importance of
VEGFs and PDGFs and their receptors in both tumor cells
and stroma.22–24 In this study, our aim was, based on appeal-
ing preclinical results, to explore the (1) prognostic signifi-
cance of FGF2 and FGFR-1 expression in both tumor cells
and stroma of resected NSCLC patients and (2) their coex-
pression with PDGF-B and VEGFR-3.
PATIENTS AND METHODS
Patients and Clinical Samples
Primary tumor tissues from anonymized patients diag-
nosed with NSCLC pathologic stage I to IIIA at the Univer-
sity Hospital of Northern Norway and Nordland Central
Hospital from 1990 through 2004 were used in this retrospec-
tive study. In total, 371 patients were registered from the
hospital database. Of these, 36 patients were excluded from
the study due to: (i) Radiotherapy or chemotherapy before
surgery (n 10); (ii) Other malignancy within 5 years before
NSCLC diagnosis (n  13); (iii) Inadequate paraffin-embed-
ded fixed tissue blocks (n 13). Adjuvant chemotherapy was
not introduced in Norway during this period (1990–2004).
Thus, 335 patients with complete medical records and ade-
quate paraffin-embedded tissue blocks were eligible.
This report includes follow-up data as of September 30,
2005. The median follow-up was 96 (range, 10–179) months.
Complete demographic and clinical data were collected ret-
rospectively. Formalin-fixed and paraffin-embedded tumor
specimens were obtained from the archives of the Depart-
ments of Pathology at University Hospital of Northern Nor-
way and Nordland Central Hospital. The tumors were staged
according to the International Union Against Cancer’s tumor,
node, metastasis classification and histologically subtyped
and graded according to the World Health Organization
guidelines.25 The National Data Inspection Board and The
Regional Committee for Research Ethics approved the study.
Microarray Construction
All lung cancer cases were histologically reviewed by 2
pathologists (S.A.S.) and (K.A.S.) and the most representa-
tive areas of tumor cells (neoplastic epithelial cells) and
tumor stroma were carefully selected and marked on the
hematoxylin and eosin (H/E) slide and sampled for the tissue
microarray blocks (TMAs). The TMAs were assembled using a
tissue-arraying instrument (Beecher Instruments, Silver Springs,
MD). The Detailed methodology has been previously reported.22
Briefly, we used a 0.6 mm diameter stylet, and the study
specimens were routinely sampled with two replicate core sam-
ples (different areas) of neoplastic tissue and two of tumor
stroma. Both normal lung tissue localized distant from the
primary tumor, and one slide with normal lung tissue samples
from 20 patients without a cancer diagnosis, were used as
negative controls.
To include all core samples, eight tissue array blocks
were constructed. Multiple 5-m sections were cut with a
Micron microtome (HM355S) and stained by specific anti-
bodies for immunohistochemistry (IHC) analysis.
Immunohistochemistry (IHC)
The applied antibodies were subjected to in-house val-
idation by the manufacturer for IHC analysis on paraffin-
embedded material. The antibodies used in the study were
FGF2 (rabbit polyclonal; AB1458; Chemicon; 1:200) and
FGFR-1 (rabbit polyclonal; sc-121; Santa Cruz; 1:50). The
IHC procedures for VEGFR-3 and PDGF-B have been de-
scribed earlier.22–24
Sections were deparaffinised with xylene and rehy-
drated with ethanol. Antigen retrieval was performed by
placing the specimen in 0.01M citrate buffer at pH 6.0 and
exposed to microwave heating of 10 minutes at 250W (FGF2)
or heated by pressure boiler of 2 minutes (FGFR-1). The
DAKO EnVision  System-HRP (DAB) kit was used as
endogen peroxidase blocking. As negative staining controls,
the primary antibodies were replaced with the primary anti-
body diluent. For antibodies where the pathologists where
uncertain about the specificity, based on morphologic criteria,
isotype control was done (VEGFR-3). Primary antibodies
were incubated for 30 minutes (FGF2) or 60 minutes
(FGFR-1) in room temperature. The kit DAKO EnVision 
System-HRP (DAB) was used to visualize the antigens. This
was followed by application of liquid diaminobenzidine and
substrate-chromogen, yielding a brown reaction product at
the site of the target antigen. Finally, all slides were counter-
stained with hematoxylin to visualize the nuclei. For each
antibody, included negative staining controls, all TMA stain-
ing were performed in a single experiment.
Scoring of Immunohistochemistry
By light microscopy, representative and viable tissue
sections were scored semiquantitatively for cytoplasmic
staining. The dominant staining intensity in both tumor cells
and stromal cells was scored as: 0 negative; 1 weak; 2
intermediate; 3  strong (Figure 1). The cell density of the
stroma was scored as: 1  low density; 2  intermediate
density; 3  high density (Figure 1). All samples were
anonymised and independently scored by 2 pathologists
(S.A.S. and K.A.S.). In case of disagreement the slides were
reexamined and a consensus was reached by the observers. In
most tumor cores as well as in some stromal cores there is a
mixture of stromal cells and tumor cells. However, by mor-
phologic criteria we have only scored staining intensity of
tumor cells in tumor cores and intensity and density of
stromal cells in stromal cores. When assessing a variable for
a given core, the observers were blinded to the scores of the
other variables and to outcome. The interobserver scoring
agreement has previously been found valid in the same
TMA-blocks for one ligand and one receptor with similar
cytoplasmic staining.22 After categorizing into high and low
expression group, the percentage discordance among the
pathologists was: Tumor cell ligand 8%, stromal ligand 8%,
tumor cell receptor 2%, and stromal receptor 4%. Mean score
for duplicate cores from each individual was calculated sep-
arately in tumor cells and stroma. High expression in tumor
cells was defined as score 1 (FGFR-1) or  3 (FGF2).
Stromal expression was calculated by summarizing density
score (1–3) and intensity score (0–3) before categorizing into
low and high expression. High stromal expression was de-
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fined as score 4.5 (FGF2) or 4 (FGFR-1). The predefined
cutoff values for VEGFR-3 and PDGF-B,22–24 were used to
estimate the coexpressions with FGF2 and FGFR-1.
Statistical Methods
All statistical analyses were done using the statistical
package SPSS (Chicago, IL), version 15. The 2 test and
Fisher’s exact test were used to examine the association
between molecular marker expression and various clinico-
pathological parameters. Univariate analysis was done by
using the Kaplan-Meier method, and statistical signifi-
cance between survival curves was assessed by the log-
rank test. Disease-specific survival (DSS) was determined
from the date of surgery to the time of lung cancer death.
To assess the independent value of different pretreatment
variables on survival, in the presence of other variables,
multivariate analysis was carried out using the Cox pro-
portional hazards model. Only variables of significant
value from the univariate analysis were entered into the
Cox regression analysis. Probability for stepwise entry and
removal was set at 0.05 and 0.10, respectively. The sig-
nificance level was set at p  0.05.
RESULTS
Clinicopathologic Variables
Demographic, clinical, and histopathologic variables
are shown in Table 1. The median age was 67 (range, 28–85)
years and the majority of patients were male (75%). The
NSCLC tumors comprised 191 squamous cell carcinomas
(SCCs), 95 adenocarcinomas, 31 large-cell carcinomas (LCCs),
and 18 bronchioalveolar carcinomas (BACs). Due to nodal
metastasis or nonradical surgical margins, 59 patients (18%)
received postoperative radiotherapy.
Expression of FGF2 and FGFR-1 and their
Correlations
FGFR-1 and FGF2 were expressed in the cytoplasm of
tumor cells. Based on morphologic criteria, FGFR-1 showed
primarily moderate staining intensity in pneumocytes in con-
trol cores. Lymphocytes showed all degrees of staining inten-
sity, approximately 1/3 was negative, 1/3 was weakly positive,
and 1/3 moderately to strongly positive. Macrophages and
plasma cells were stained strongly positive in both control and
stromal cores. Bronchial epithelium showed moderate or pos-
itive staining intensity although endothelial blood vessel cells
in control cores were mostly negative and tumor cells weakly
positive. Fibroblast-like cells were weakly stained in both
control cores and tumor tissue.
There was a moderate FGF2 expression in pneumo-
cytes. Lymphocytes were approximately 50% weakly pos-
itive and 50% negative in control cores, while near all
lymphocytes showed moderate to strong staining in tumor
stroma. Plasma cells and macrophages showed moderate to
strong staining in both control cores and tumor stroma.
Bronchial epithelium showed weak staining intensity al-
though the endothelium was primarily weakly positive in
both control cores and tumor stroma. Fibroblast-like cells
were generally weakly stained in both control cores and
tumor tissue.
Tumor or stromal cell FGF2 or FGFR1 expression
did not correlate with age, performance status, tumor
differentiation, or vascular infiltration. Tumor cell FGF2
was more frequently expressed in node positive patients
(high expression; N0 6%, N1 15%, N2 15%, p  0.024).
Besides, stromal expression of FGF2 was significant re-
duced in LCC (high expression; LCC 7%, BAC 28%, SCC
29%, adenocarcinomas 20%, p  0.029), T2-tumors (high
expression; T1 32%, T2 20%, T3 33%, p  0.044) and
tumors with positive surgical margins (high expression;
margins free 26%, margins not free 7%, p  0.016).
Tumor cell FGFR-1 was more frequently expressed in
females (high expression; females 82%, males 64%, p 
0.004), in patients without weight loss (high expression;
weight loss 50%, no weight loss 70%) and in BAC and
adenocarcinomas (high expression; LCC 58%, BAC 89%,
SCC 62%, adenocarcinomas 82%, p  0.001). Stromal
FGFR-1 was more often expressed in tumors with T1-status
(high expression; T1 33%, T2 21%, T3 18%, p  0.049).
Univariate Analysis
Among the clinical variables, shown in Table 1,
performance status (p  0.04), differentiation (p  0.001),
surgical procedure (p  0.0009), pathologic stage (p 
0.0001), T-stage (p  0.002), N-stage (p  0.0001),
vascular infiltration (p  0.0005), and postoperative ra-
diotherapy (p  0.002) were all significant prognostic
FIGURE 1. Immunohistochemical analysis of tissue microar-
ray block (TMA) of non-small cell lung cancer (NSCLC) rep-
resenting different score for tumor cell basic fibroblast
growth factor (FGF2) and stromal FGF2; (A) Tumor cell FGF2
score 1; (B) Tumor cell FGF2 score 3; (C) Stromal FGF2 low
score (density 1, intensity 0); (D) Stromal FGF2 high score
(density 3, intensity 3).
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TABLE 1. Prognostic Clinicopathologic Variables as Predictors for Disease-Specific Survival in 335
NSCLC Patients (Univariate Analysis; Log-Rank Test)
Characteristic
Patients
(n)
Patients
(%)
Median
Survival
(Mo)
5-Year
Survival
(%) p
Age
65 yr 156 47 104 57 0.62
65 yr 179 53 NR 58
Sex
Female 82 25 127 65 0.19
Male 253 75 84 55
Smoking
Never 15 5 19 43 0.13
Current 215 64 NR 60
Former 105 31 84 54
Performance status
ECOG 0 197 59 NR 62 0.04
ECOG 1 120 36 61 52
ECOG 2 18 5 36 40
Weight loss
10% 303 90 127 57 0.92
10% 32 10 NR 57
Histology
SCC 191 57 NR 65 0.30
Adenocarcinoma 95 28 52 44
BAC 18 5 NR 67
LCC 31 9 84 54
Differentiation
Poor 138 41 48 48 0.001
Moderate 144 43 NR 64
Well 53 16 NR 65
Surgical procedure
Lobectomy  Wedgea 243 73 NR 61 0.0009
Pneumonectomy 92 27 35 46
Stage
I 212 63 NR 68 0.0001
II 91 27 41 46
IIIa 32 10 18 22
Tumor status
1 90 27 NR 75 0.002
2 218 65 84 52
3 27 8 42 43
Nodal status
0 232 69 NR 66 0.0001
1 76 23 37 43
2 27 8 18 20
Surgical margins
Free 307 92 127 58 0.34
Not free 28 8 64 51
Vascular infiltration
No 284 85 NR 61 0.0005
Yes 51 15 25 35
Postoperative radiotherapy
No 276 82 NR 61 0.002
Yes 59 18 41 42
a Wedge, n  10.
NR, not reached; ECOG, Eastern Cooperative Oncology Group; SCC squamous cell carcinoma; BAC, bronchioalveolar carcinoma; LCC,
large-cell carcinoma; NSCLC, non-small cell lung cancer.
Journal of Thoracic Oncology • Volume 4, Number 5, May 2009 Fibroblast Growth Factors in NSCLC
Copyright © 2009 by the International Association for the Study of Lung Cancer 581
indicators for DSS. The influence on survival by tumor cell
and stromal expression of FGF2 and FGFR-1 are shown in
Table 2 and Figure 2. In univariate analyses, tumor cell
FGF2 expression (p  0.015; Figure 2A) and stromal
FGF2 expression (p  0.024; Figure 2B) were prognostic,
but opposite indicators for DSS.
Multivariate Cox Proportional Hazards Analysis
Results of the multivariate analysis are presented in
Table 3. Including significant clinicopathological and angio-
genic variables from the univariate analysis, tumor cell FGF2
(p  0.038), stromal FGF2 expression (p  0.015), perfor-
TABLE 2. Tumor Cell and Stromal Angiogenic Markers as Predictors for Disease-Specific Survival
in 335 NSCLC Patients (Univariate Analysis; Log-Rank Test)
Marker Expression
Patients
(n)
Patients
(%)
Median
Survival
(Mo)
5-Year
Survival (%) p
FGF2
Tumor
Low 307 92 NR 59 0.015
High 28 8 24 37
Stroma
Low 253 76 83 53 0.024
High 82 24 NR 70
FGFR-1
Tumor
Low 105 31 NR 61 0.15
High 230 69 83 56
Stroma
Low 254 76 104 56 0.37
High 80 24 127 63
Missing 1 0
FGF2 and VEGFR-3
Tumor cell
Low FGF2 low VEGFR-3 199 59 NR 64 0.001
Low FGF2 high VEGFR-3 104 31 63 50
High FGF2 low VEGFR-3 12 4 NR 72
High FGF2 high VEGFR-3 16 5 22 10
Missing 4 1
FGFR-1 and VEGFR-3
Tumor cell
Low FGFR-1 low VEGFR-3 85 25 NR 70 0.001
Low FGFR-1 high VEGFR-3 20 6 26 30
High FGFR-1 low VEGFR-3 126 38 NR 62
High FGFR-1 high VEGFR-3 100 30 51 48
Missing 4 1
FGF2 and PDGF-B
Tumor cell
Low FGF2 low PDGF-B 262 78 NR 62 0.002
Low FGF2 high PDGF-B 44 13 32 45
High FGF2 low PDGF-B 20 6 43 35
High FGF2 high PDGF-B 8 3 11 37
Missing 1 0
FGFR-1 and PDGF-B
Tumor cell
Low FGFR-1 low PDGF-B 97 29 NR 61 0.002
Low FGFR-1 high PDGF-B 8 3 NR 63
High FGFR-1 low PDGF-B 185 55 127 59
High FGFR-1 high PDGF-B 44 13 21 41
Missing 1 0
NR, not reached; FGF-2, Fibroblast growth factor 2; PDGF-B, platelet-derived growth factor–B; VEGFR-3, vascular endothelial growth
factor-3; FGFR-1, fibroblast growth factor receptor-1; NSCLC, non-small cell lung cancer.
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mance status (p  0.012), pathologic T-stage (p  0.02),
N-stage (p  0.001), histologic differentiation (p  0.042),
and vascular infiltration (p  0.005) seemed as independent
prognostic factors.
Coexpression of FGF2/FGFR1 with VEGFR-3
and PDGF-B
Table 2 and Figure 3 show the DSS rates of the patients
stratified into four groups according to the basis of high or
low FGF2 or FGFR1 expression versus a high or low
VEGFR-3 or PDGF-B expression. The coexpression of tumor
cell FGF2/VEGFR-3 (p  0.001), FGF2/PDGF-B (p 
0.002), FGFR-1/VEGFR-3 (p  0.001), and FGFR-1/
PDGF-B (p  0.002), were all significant prognostic indica-
tors for DSS.
Examining the same combinations of stromal coexpres-
sions, there were no significant associations with survival
(stromal FGF2/VEGFR-3, p  0.10; stromal FGF2/PDGF-B,
p  0.052; stromal FGFR-1/VEGFR-3, p  0.73; stromal
FGFR-1/PDGF-B, p  0.24).
The coexpression of tumor cell FGF2/VEGFR-3 (high
FGF2/high VEGFR-3: N0 2,2%; N1 9,3%; N2 14,8%, p 
0.001) and FGFR-1/VEGFR-3 (high FGFR-1/high VEGFR-3:
N0 25%; N1 30%; N2 70%, p  0.001) correlated significantly
with lymph node metastasis, whereas the coexpression of tumor
cell FGF2/PDGF-B (p  0.07) and FGFR-1/PDGF-B (p 
0.09) tended to, but did not reach a significant level.
DISCUSSION
We present a large-scale study in an unselected popu-
lation of surgically resected NSCLC patients using high-
throughput TMA methodology to examine the prognostic
impact of FGF2 and FGFR-1 and their coexpressions with
VEGFR-3 and PDGF-B in both tumor cells and stroma. High
tumor cell FGF2 expression is an independent negative prog-
nostic indicator for DSS, although high stromal FGF2 expres-
sion correlates with a good prognosis. Interestingly, tumor
cell coexpressions of both FGF2/VEGFR-3 and of FGFR-1/
PDGF-B correlated significantly with a poor prognosis.
The prognostic impact of FGF2 in NSCLC is still contro-
versial. Corroborating our results, some previous studies have
found tumor cell FGF2 expression to be a negative prognostic
factor.8,10,11 In a cohort of 119 resected NSCLC patients, Shou
et al.,10 reported FGF2 as a negative prognosticator, though only
in the univariate analysis. However, in a study of 167 stage I-IV
NSCLC adenocarcinomas,11 FGF2 seemed as an independent
indicator of poor prognosis while FGFR-1 had a negative prog-
nostic impact in the univariate analysis. Using frozen tissue and
enzyme-linked immunosorbent assay technique, in a cohort of
71 resected NSCLC patients, Iwasaki et al.8 observed that FGF2
had an independent negative impact on survival. In contrast,
other studies revealed no correlation between tumor cell FGF2
expression and survival.9,12 In a relatively large study, involving
206 resected NSCLC tumors, Volm et al.12 found FGFR-1, but
not FGF2, in univariate analysis to correlate with a poor prog-
nosis. In addition, Kojima et al.9 did not observe a negative
prognostic impact of tumor FGF2 expression in a cohort of 132
stage I NSCLC patients.
Studies on FGF2 serum levels in NSCLC patients have
been contradictory with respect to prognostic relevance.14–18
One study reported high serum level of FGF2 to indicate a
favorable prognosis.14 The latter may be explained by our
finding of high stromal FGF2 expression as a favorable prog-
nostic indicator. It can be argued that both stromal and tumor
cell FGF2 may contribute to the serum level of FGF2. To our
knowledge, this is the first study reporting stromal FGF2 ex-
pression to correlate with a good prognosis in NSCLC. Never-
theless, in 84 stage I-IIIA NSCLC patients, Guddo et al.13
reported stromal FGF2 to inversely correlate with lymph node
metastasis, indicating an inhibitory role in NSCLC progression.
Corroborating the findings by Guddo et al.,13 we have previously
reported stromal VEGFs and VEGFRs to be correlated with
increased survival,22 though the mechanisms behind these find-
ings is not fully understood.
It has to be noted that the stromal expression of each
marker is the total expression of the different stromal com-
ponents, including lymphocytes, macrophages, granulocytes
and fibroblast-like cells. Thus, the stromal FGF2 expression
FIGURE 2. Disease-specific survival curves according to; (A)
tumor cell basic growth factor (FGF2) expression; (B) stromal
FGF2 expression.
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may be linked to one or more stromal cell types. Almost all
lymphocytes were moderately to strongly FGF2 positive in
tumor stroma and activation of the adaptive immune system
may suppress malignant cell proliferation.26 Hence, high
stromal FGF2 may to some extent reflect activation of the
adaptive immune system, which corroborate our previous
results in this cohort.27
This is the first study investigating the prognostic im-
pact of the coexpression of FGF2 and VEGFR-3 in a large
cohort of cancer patients. Beyond being expressed in lym-
phatics, VEGFR-3 is also up-regulated in blood vessels in
several cancers.28,29 FGF2 is well established as an important
mediator in angiogenesis, but also considered of importance
in lymphangiogenesis. Actually, FGF2 pellets implanted in
mouse cornea demonstrated the lymphatics to be more respon-
sive to FGF2 than the blood vessels.30 It has been demonstrated
that cross-talk between VEGFs and FGFs may occur in both
hemangiogenesis and lymphanigiogenesis.4 In a study by Chang
et al.31 it was proposed that the lymphatic activity of FGF2 is
mediated by endogenous VEGF-C and VEGF-D, leading to
VEGFR-3 activation. Hence, in the study by Kubo et al.21
administration of anti-VEGFR-3 antibodies inhibited the FGF2
lymphangiogenesis in mouse cornea.
Tumor lymphangiogenesis has been associated with
lymphatic metastasis, although the precise mechanism is not
fully understood.21,32 Albeit only 16 patients were in the
subgroup of high FGF2/high VEGFR-3 expression, this co-
expression of FGF2 and VEGFR-3 seems strongly associ-
ated with poor survival. In our previous reports, tumor cell
VEGFR-3 expression correlated with both nodal status and
survival.22,23 Herein, we find FGF2 alone and the coexpres-
sion of FGF2/VEGFR-3 and FGFR-1/VEGFR-3 to be signif-
icantly associated with lymph node metastasis. Actually, in
the group of N2 patients, 70% of the patients (19 of 27) had
high FGFR-1/high VEGFR-3 expression, indicating lym-
phangiogenesis as a plausible contributor to poor survival.
Of interest, Nissen et al.20 recently reported a reciprocal
interaction between FGF2 and PDGF-B in a murine tumor
model, leading to neovascularization and metastasis. The
simultaneous overexpression of FGF2 and PDGF-B resulted
in a formation of high-density primitive vascular plexuses,
which were poorly coated with pericytes and vascular smooth
muscle cells (VSMCs). The underlying mechanisms of this
FIGURE 3. Disease-specific survival curves according to; (A)
coexpression basic growth factor (FGF2) and vascular endo-
thelial growth factor receptor (VEGFR)-3; (B) coexpression
fibroblast growth factor receptor (FGFR)-1 and platelet-de-
rived growth factor (PDGF)-B.
TABLE 3. Results of Cox Regression Analysis Summarizing
Significant Independent Prognostic Factors
Factor Hazard Ratio 95% CI p
Tumor status 0.02a
1 1.00
2 1.67 1.02–2.74 0.043
3 2.61 1.31–5.21 0.006
Nodal status 0.001a
0 1.00
1 2.14 1.41–3.27 0.001
2 2.75 1.59–4.77 0.001
Performance status 0.012a
ECOG 0 1.00
ECOG 1 1.76 1.19–2.60 0.005
ECOG 2 1.81 0.81–4.02 0.15
Vascular infiltration
No 1.00
Yes 2.00 1.23–3.22 0.005
Differentiation 0.042a
Poor 1.00
Moderate 0.60 0.40–0.90 0.012
Well 0.73 0.41–1.34 0.32
FGF2 tumor
Low 1.00
High 1.80 1.03–3.14 0.038
FGF2 stroma
Low 1.78 1.12–2.83 0.015
High 1.00
a Overall significance as a prognostic factor.
FGF-2, Fibroblast growth factor 2; ECOG, Eastern Cooperative Oncology Group;
CI, confidence interval.
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reciprocal interaction involve FGF2 associated up-regulation
of PDGF receptors in endothelial cells and PDGF-B associ-
ated up-regulation of FGFR-1 in VSMCs. In our study, there
is coexpression of high FGF2/high PDGF-B in only 8 pa-
tients. But these patients had a significantly shortened sur-
vival (37% 5-year survival) when compared with the low
FGF2/low PDGF-B group (62% 5-year survival, p  0.002).
The fact that 86% of patients (24 of 28) with high tumor cell
FGF2 expression also had high tumor cell FGFR-1 expres-
sion indicates an autocrine loop in the tumor cells. Although
these findings are related to tumor cell expression, we may
speculate that high production of these angiogenic factors in
the tumor cells may also act in a paracrine fashion to stimu-
late pericytes, VSMCs and endothelial cells.
The VEGFs, PDGFs, and FGFs are all essential in tumor
development and different novel targeted therapies aim to inhibit
one ore more of these angiogenic markers. Herein, tumor cell
FGF2 expression emerged as an independent negative prognos-
tic factor for stage I-IIIA NSCLC while high stromal FGF2
expression favors a good prognosis. Supporting previous pre-
clinical findings, we have for the first time shown that coexpres-
sions of FGF2/VEGFR-3 and FGFR-1/PDGF-B seem to be
significant prognosticators in NSCLC. Based on these results, a
multitargeted antiangiogenic approach may be more promising
than inhibiting single targets in the treatment of NSCLC patients.
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